Orforglipron is a once-daily, small-molecule, non-peptide, partial GLP-1 RA, which can be administered orally without any special precautions in relation to food or drink
It takes approximately four to five weeks of consistent weekly dosing for semaglutide to reach what researchers call steady-state concentration in your bloodstream
Persistent hunger despite adequate dosing, inadequate glycaemic control, or concerning symptoms such as severe abdominal pain warrant discussion with your GP or diabetes specialist nurse
Many insurance providers may cover the medication if it is prescribed for obesity or weight-related conditions such as diabetes, high blood pressure, or metabolic syndrome
If you experience severe nausea, vomiting, abdominal pain, or inability to tolerate food or fluids after resuming semaglutide, contact your healthcare provider immediately, as these symptoms could indicate either medication intolerance or a postoperative complication requiring evaluation
Here's to a lighter, brighter future
